Dr. Nicolas Palaskas, MD

Dr. Palaskas practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Palaskas' NPI, 1396037982, was assigned on May 14, 2011. Dr. Palaskas graduated from Joe R. & Teresa Lozano Long School of Medicine in 2011. Dr. Palaskas holds Texas license P9430.

Dr. Palaskas' primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Palaskas' primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Palaskas practices. Vendor and product names are available with a free account.

Cardiovascular disease is Dr. Palaskas' primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dmand AI has Dr. Palaskas' licenses on file in 10 states: Texas, Florida, Arizona, Mississippi, Tennessee, Washington, Alabama, Georgia, Louisiana and Oklahoma.

Dmand AI lists aneurysm, atrial fibrillation and flutter, cardiac catheterization, cardiomyopathy, chronic hypertension, coronary artery disease, endocarditis and heart blockage among the conditions Dr. Palaskas treats.

CMS data shows 892 Medicare services from Dr. Palaskas across 10 procedure codes in 2024, for 783 Medicare patients. Medicare paid $43,573 for them.

CMS counts 783 Medicare patients who saw Dr. Palaskas in 2024. The largest group is 65 to 74, with 419 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 5% are also on Medicaid. Their average risk score is 2.88, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Palaskas' median patient age at 70, with 48% women.

In 2024, Dr. Palaskas wrote 685 Medicare Part D claims for 145 patients. 88% of them were for generic drugs. CMS names the drug for 533 of them, across 18 drugs with 11 or more claims each, at $60,425 in total drug cost. In 2023, CMS named 544 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Palaskas for performance year 2024, reported as part of a group. Dr. Palaskas accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Palaskas as offering telehealth.

Dmand AI links 119 papers to Dr. Palaskas, published from 2016 to 2025. 2020 was the busiest year, with 22. The most frequent topics are Immune Checkpoint Inhibitors, Myocarditis and Cardiotoxicity. Dr. Palaskas has published most often in Front Cardiovasc Med. Dr. Palaskas' most frequent co-authors are Cezar A. Iliescu, MD, Anita Deswal, MD and Juan Carlos Lopez-Mattei, MD.

Dmand AI links Dr. Palaskas to 1 clinical trial.

CMS Open Payments shows 131 general payments to Dr. Palaskas from 22 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. St. Jude Medical, Inc. paid the most, $1,149.

Dr. Palaskas graduated from Joe R. & Teresa Lozano Long School of Medicine in 2011.

Dr. Palaskas is in network with 16 carriers, including Aetna, Excellus BlueCross BlueShield and United Healthcare. HMO plans come from the most carriers, 10. Check the plan with the practice before a visit.